奥利司他所致草酸盐肾病：慢性肾脏病一个未得到充分认识的病因。
Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.
作者信息
Solomon Laurence Richard, Nixon Andrew Christopher, Ogden Leanne, Nair Beena
机构信息
Department of Renal Medicine, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
Department of Histopathology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
出版信息
BMJ Case Rep. 2017 Nov 12;2017:bcr-2016-218623. doi: 10.1136/bcr-2016-218623.
Abstract
Two patients developed kidney failure due to oxalate deposition in the kidney while taking orlistat. Cessation of orlistat was followed by partial recovery of kidney function. The mechanism by which orlistat causes hyperoxaluria and the management of orlistat-induced oxalate nephropathy is reviewed. We suggest that all patients taking orlistat are at risk of this condition, which may develop insidiously and is easily overlooked. Monitoring of kidney function of patients taking orlistat is warranted.
摘要
两名患者在服用奥利司他期间因草酸在肾脏沉积而出现肾衰竭。停用奥利司他后，肾功能部分恢复。本文综述了奥利司他导致高草酸尿症的机制以及奥利司他所致草酸肾病的治疗方法。我们认为，所有服用奥利司他的患者都有患此病的风险，该病可能隐匿发展且容易被忽视。对服用奥利司他的患者进行肾功能监测是必要的。
相似文献
1
Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.奥利司他所致草酸盐肾病：慢性肾脏病一个未得到充分认识的病因。
BMJ Case Rep. 2017 Nov 12;2017:bcr-2016-218623. doi: 10.1136/bcr-2016-218623.
2
Weight loss at a high cost: Orlistat-induced late-onset severe kidney disease.高代价的体重减轻：奥利司他诱发的迟发性严重肾病。
Diabetes Metab. 2016 Feb;42(1):62-4. doi: 10.1016/j.diabet.2015.08.006. Epub 2015 Oct 9.
3
An unusual complication of treatment with orlistat.奥利司他治疗的一种罕见并发症。
Clin Nephrol. 2009 Apr;71(4):430-2. doi: 10.5414/cnp71430.
4
When the Cause Is Not Crystal Clear.
N Engl J Med. 2020 Jan 2;382(1):74-78. doi: 10.1056/NEJMcps1809996.
5
Is there a link between calcium oxalate crystalluria, orlistat and acute tubular necrosis?草酸钙结晶尿、奥利司他与急性肾小管坏死之间存在关联吗？
Nephrol Dial Transplant. 2008 May;23(5):1778-9. doi: 10.1093/ndt/gfm945. Epub 2008 Feb 13.
6
Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria.奥利司他诱导的肠道高草酸尿症继发急性草酸肾病
Nephrology (Carlton). 2013 Mar;18(3):241-2. doi: 10.1111/j.1440-1797.2012.01649.x.
7
Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.奥利司他所致的草酸肾病可能与剂量无关，并表现为晚期症状。
J La State Med Soc. 2013 Sep-Oct;165(5):283-5.
8
Orlistat and calcium oxalate crystalluria: an association that needs consideration.奥利司他与草酸钙结晶尿：需要考虑的关联。
Ren Fail. 2010;32(8):1019-21. doi: 10.3109/0886022X.2010.501929.
9
Orlistat, an under-recognised cause of progressive renal impairment.奥利司他，一种逐渐引起肾损伤而未被充分认识的原因。
Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv172-4. doi: 10.1093/ndt/gft066. Epub 2013 Sep 18.
10
Acute oxalate nephropathy associated with orlistat, a gastrointestinal lipase inhibitor.与胃肠道脂肪酶抑制剂奥利司他相关的急性草酸盐肾病。
Am J Kidney Dis. 2007 Jan;49(1):153-7. doi: 10.1053/j.ajkd.2006.10.004.
引用本文的文献
1
Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database.基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库的奥利司他不良事件的药物警戒分析。
Heliyon. 2024 Jul 18;10(14):e34837. doi: 10.1016/j.heliyon.2024.e34837. eCollection 2024 Jul 30.
2
Assessment and management of chronic kidney disease in people living with obesity.肥胖人群慢性肾脏病的评估与管理。
Clin Med (Lond). 2023 Jul;23(4):353-356. doi: 10.7861/clinmed.2023-0195.
3
Current and emerging medications for the management of obesity in adults.用于成人肥胖管理的现有及新出现的药物。
Med J Aust. 2023 Apr 3;218(6):276-283. doi: 10.5694/mja2.51871. Epub 2023 Mar 19.
4
Oxalate crystal-related acute renal injury caused by orlistat: A case report.奥利司他致草酸盐晶体相关性急性肾损伤 1 例报告。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 May 28;47(5):583-587. doi: 10.11817/j.issn.1672-7347.2022.210393.
5
Case - Orlistat-induced calcium oxalate crystalluria.病例——奥利司他诱导的草酸钙结晶尿症。
Can Urol Assoc J. 2022 Oct;16(10):371-373. doi: 10.5489/cuaj.7900.
6
Management of Obesity in Adults with CKD.慢性肾脏病成人患者的肥胖管理
J Am Soc Nephrol. 2021 Apr;32(4):777-790. doi: 10.1681/ASN.2020101472. Epub 2021 Feb 18.
7
Metabolic Surgery to Treat Obesity in Diabetic Kidney Disease, Chronic Kidney Disease, and End-Stage Kidney Disease; What Are the Unanswered Questions?代谢手术治疗糖尿病肾病、慢性肾脏病和终末期肾病的肥胖症：有哪些未解答的问题？
Front Endocrinol (Lausanne). 2020 Aug 17;11:289. doi: 10.3389/fendo.2020.00289. eCollection 2020.
8
Calcium oxalate crystal deposition in the kidney: identification, causes and consequences.肾脏草酸钙晶体沉积：鉴定、病因与后果。
Urolithiasis. 2020 Oct;48(5):377-384. doi: 10.1007/s00240-020-01202-w. Epub 2020 Jul 27.
9
Secondary Oxalate Nephropathy: A Systematic Review.继发性草酸盐肾病：一项系统评价
Kidney Int Rep. 2018 Jul 29;3(6):1363-1372. doi: 10.1016/j.ekir.2018.07.020. eCollection 2018 Nov.
10
Medical therapy for nephrolithiasis: State of the art.肾结石的药物治疗：最新进展
Asian J Urol. 2018 Oct;5(4):243-255. doi: 10.1016/j.ajur.2018.08.005. Epub 2018 Sep 3.
本文引用的文献
1
AJKD Atlas of Renal Pathology: Oxalosis.
Am J Kidney Dis. 2017 Mar;69(3):e13-e14. doi: 10.1053/j.ajkd.2017.01.006.
2
Acute oxalate nephropathy associated with orlistat.与奥利司他相关的急性草酸盐肾病
J Nephropathol. 2016 Apr;5(2):79-83. doi: 10.15171/jnp.2016.14. Epub 2016 Mar 29.
3
The management of patients with enteric hyperoxaluria.肠源性高草酸尿症患者的管理
Urolithiasis. 2016 Feb;44(1):33-43. doi: 10.1007/s00240-015-0846-5. Epub 2015 Dec 8.
4
Enteric hyperoxaluria: an important cause of end-stage kidney disease.肠道高草酸尿症：终末期肾病的一个重要原因。
Nephrol Dial Transplant. 2016 Mar;31(3):375-82. doi: 10.1093/ndt/gfv005. Epub 2015 Feb 20.
5
Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis.活性氧、炎症与草酸钙肾结石
Transl Androl Urol. 2014 Sep 1;3(3):256-276. doi: 10.3978/j.issn.2223-4683.2014.06.04.
6
Acute oxalate nephropathy associated with orlistat: a case report with a review of the literature.与奥利司他相关的急性草酸盐肾病：一例病例报告并文献复习
Case Rep Nephrol. 2013;2013:124604. doi: 10.1155/2013/124604. Epub 2013 May 8.
7
Orlistat-induced oxalate nephropathy may be dose-independent and present as a late manifestation.奥利司他所致的草酸肾病可能与剂量无关，并表现为晚期症状。
J La State Med Soc. 2013 Sep-Oct;165(5):283-5.
8
Obesity in CKD--what should nephrologists know?慢性肾脏病患者中的肥胖症——肾科医生应该了解哪些内容？
J Am Soc Nephrol. 2013 Nov;24(11):1727-36. doi: 10.1681/ASN.2013040330. Epub 2013 Oct 10.
9
Orlistat, an under-recognised cause of progressive renal impairment.奥利司他，一种逐渐引起肾损伤而未被充分认识的原因。
Nephrol Dial Transplant. 2013 Nov;28 Suppl 4:iv172-4. doi: 10.1093/ndt/gft066. Epub 2013 Sep 18.
10
NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy.NALP3 介导的炎症是草酸肾病进行性肾功能衰竭的主要原因。
Kidney Int. 2013 Nov;84(5):895-901. doi: 10.1038/ki.2013.207. Epub 2013 Jun 5.
Zotero 插件